Balaxi (BALAXI) | Financial Analysis & Statements
Balaxi Pharmaceuticals Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
707.4M
Gross Profit
311.8M
44.08%
Operating Income
36.9M
5.21%
Net Income
2.9M
0.41%
EPS (Diluted)
₹0.05
Balance Sheet Metrics
Total Assets
3.1B
Total Liabilities
786.1M
Shareholders Equity
2.3B
Debt to Equity
0.34
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Balaxi Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.9B | 2.4B | 3.4B | 2.8B | 2.3B |
| Cost of Goods Sold | 1.7B | 1.3B | 2.0B | 2.0B | 1.7B |
| Gross Profit | 1.3B | 1.1B | 1.3B | 837.9M | 591.9M |
| Gross Margin % | 43.4% | 46.7% | 39.8% | 30.0% | 25.6% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 451.5M | 284.5M | 321.0M | 141.6M | 56.6M |
| Other Operating Expenses | 2.4M | 2.1M | 47.5M | 23.7M | 6.5M |
| Total Operating Expenses | 453.9M | 286.6M | 368.5M | 165.3M | 63.1M |
| Operating Income | 364.0M | 457.9M | 556.6M | 503.1M | 424.2M |
| Operating Margin % | 12.4% | 19.0% | 16.5% | 18.0% | 18.3% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | 18.0K |
| Interest Expense | 29.3M | 16.8M | 5.0M | 1.4M | 184.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 286.7M | 20.2M | 569.2M | 545.2M | 443.3M |
| Income Tax | 36.0M | 44.0M | 109.6M | 68.6M | 61.9M |
| Effective Tax Rate % | 12.6% | 218.4% | 19.3% | 12.6% | 14.0% |
| Net Income | 250.7M | -23.9M | 459.6M | 476.6M | 381.4M |
| Net Margin % | 8.6% | -1.0% | 13.7% | 17.1% | 16.5% |
| Key Metrics | |||||
| EBITDA | 335.0M | 441.5M | 591.7M | 551.8M | 446.8M |
| EPS (Basic) | ₹4.54 | ₹-0.46 | ₹9.16 | ₹9.53 | ₹7.63 |
| EPS (Diluted) | ₹4.54 | ₹-0.46 | ₹9.08 | ₹9.53 | ₹7.63 |
| Basic Shares Outstanding | 55207500 | 51470130 | 50167000 | 50000000 | 50000000 |
| Diluted Shares Outstanding | 55207500 | 51470130 | 50167000 | 50000000 | 50000000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Balaxi Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 394.0M | 622.9M | 282.2M | 71.9M | 16.7M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.1B | 557.1M | 522.8M | 275.6M | 761.4M |
| Inventory | 784.8M | 821.7M | 1.1B | 987.0M | 136.2M |
| Other Current Assets | 109.8M | 81.1M | 52.0M | 277.0K | 533.0K |
| Total Current Assets | 2.4B | 2.1B | 1.9B | 1.4B | 937.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 55.4M | 57.3M | 59.1M | 54.6M | -13.0K |
| Goodwill | 541.5M | 529.8M | 513.6M | 474.3M | 25.6M |
| Intangible Assets | 6.6M | 7.8M | 9.1M | 8.2M | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 45.2M | 49.8M | 19.2M | 16.7M | - |
| Total Non-Current Assets | 675.8M | 481.7M | 461.6M | 354.7M | 59.1M |
| Total Assets | 3.1B | 2.6B | 2.4B | 1.8B | 996.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 161.8M | 290.4M | 345.2M | 491.1M | 220.6M |
| Short-term Debt | 303.8M | 176.6M | 107.5M | 36.4M | 36.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 10.3M | 9.3M | 8.4M | 865.0K | 1.3M |
| Total Current Liabilities | 545.3M | 542.0M | 531.3M | 632.7M | 346.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 230.5M | 17.4M | 25.6M | 0 | 0 |
| Deferred Tax Liabilities | 9.0M | 10.0M | 11.0M | 388.0K | 71.0K |
| Other Non-Current Liabilities | - | 1.0K | -1.0K | 1.0K | -4.0K |
| Total Non-Current Liabilities | 240.7M | 27.8M | 36.6M | 389.0K | 67.0K |
| Total Liabilities | 786.1M | 569.8M | 567.9M | 633.1M | 347.0M |
| Equity | |||||
| Common Stock | 110.4M | 109.0M | 101.8M | 100.0M | 100.0M |
| Retained Earnings | 1.6B | 1.4B | 1.4B | 918.6M | 436.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.3B | 2.0B | 1.8B | 1.1B | 649.8M |
| Key Metrics | |||||
| Total Debt | 534.3M | 194.0M | 133.1M | 36.4M | 36.6M |
| Working Capital | 1.9B | 1.6B | 1.4B | 777.4M | 590.8M |
Balance Sheet Composition
Balaxi Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 286.7M | 20.2M | 569.2M | 545.2M | 443.3M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -538.2M | 164.1M | -311.1M | -416.4M | -604.3M |
| Operating Cash Flow | -196.2M | 151.8M | 320.9M | 135.5M | -169.9M |
| Investing Activities | |||||
| Capital Expenditures | -211.2M | -1.7M | -108.0M | -47.5M | -12.8M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | 0 | 0 | 0 | - | -34.2M |
| Investment Sales | 0 | 0 | 0 | 34.2M | 0 |
| Investing Cash Flow | -211.2M | -1.7M | -108.5M | -13.8M | -46.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | -5.0M | - | - |
| Debt Issuance | 339.6M | 60.4M | 79.8M | - | 36.6M |
| Debt Repayment | - | - | - | -211.0K | 0 |
| Financing Cash Flow | 367.5M | 318.7M | 259.6M | -212.0K | 36.6M |
| Free Cash Flow | -567.7M | 33.0M | -89.0M | 68.0M | -25.5M |
| Net Change in Cash | -39.9M | 468.9M | 472.0M | 121.4M | -180.3M |
Cash Flow Trend
Balaxi Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
15.75
Price to Book
0.59
Price to Sales
0.54
PEG Ratio
-0.17
Profitability Ratios
Profit Margin
3.42%
Operating Margin
3.49%
Return on Equity
10.82%
Return on Assets
8.08%
Financial Health
Current Ratio
3.96
Debt to Equity
23.75
Beta
0.16
Per Share Data
EPS (TTM)
₹1.71
Book Value per Share
₹45.56
Revenue per Share
₹51.01
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BALAXI | 1.5B | 15.75 | 0.59 | 10.82% | 3.42% | 23.75 |
| Biocon | 566.5B | 71.84 | 1.68 | 3.66% | 3.59% | 50.02 |
| OneSource Specialty | 202.8B | 936.63 | 3.11 | -0.31% | 1.42% | 21.93 |
| Zota Health Care | 39.4B | -62.53 | 12.61 | -24.83% | -15.37% | 56.90 |
| Dishman Carbogen | 26.5B | 22.30 | 0.42 | 0.06% | 4.25% | 40.20 |
| Panacea Biotec | 21.8B | 182.62 | 2.65 | -1.01% | -1.29% | 2.79 |
Financial data is updated regularly. All figures are in the company's reporting currency.





